INNOVATION
Background/Rationale: Evidence for long-term renoprotection with ARBs has come almost exclusively from Caucasian patients, despite Japanese people being at high risk of diabetic nephropathy and very susceptible to end-stage renal disease.
Objective: The objective of the INNOVATION study was to evaluate the efficacy of Pritor®/Kinzalmono® in preventing transition from microalbuminuria to overt nephropathy in Japanese patients
Study Design: The INNOVATION study was a 1-year randomised, multicenter, double-blind, placebo controlled trial with a mean duration of follow-up of 1.3 ± 0.5 years.
Makino H et al. - Diabetes Care 2007; 30(6):1577-8.
Study Endpoints:
- Primary endpoint: the transition rate from incipient to overt nephropathy (UACR 300 mg/g and increase 30% from baseline at two consecutive 4-week visits).
- Secondary endpoint was microalbuminuria remission (UACR 30 mg/g).
Results:
- Pritor®/Kinzalmono® significantly reduced the risk of transition to overt nephropathy by 66% in patients with type 2 diabetes and microalbuminuria compared to placebo.
- Pritor®/Kinzalmono® provides significant microalbuminuria remissions.
Makino H et al. - Diabetes Care 2007; 30(6):1577-8.
Conclusion:
- In Japanese normo or hypertensive patients with type 2 diabetes and microalbuminuria, Pritor®/Kinzalmono® (80 mg):
- Significantly reduced the risk of transition to overt nephropathy by 66%.
- Provided significant microalbuminuria remissions, a key goal for renal and cardiovascular protection
- Pritor®/Kinzalmono® prevents the progression to overt diabetic nephropathy and induces the regression of microalbuminuria .
